52 research outputs found
Het Schelde Informatiecentrum: een informatieplatform voor het Schelde-estuarium = The Scheldt Information Center: an information platform for the estuary of the River Scheldt
The Scheldt InformationCenter acts as an information platform for the estuary of the River Scheldt. This center is active in The Netherlands and in Flanders. Its area of interest concerns the tide-related part of the River Scheldt, i.e. from Ghent (B) to the mouth in Vlissingen (NL). The main task of the Scheldt InformationCenter is putting information about the estuary area at the disposal of everybody interested in the subject. Additionally, the institute acts as a contact point. The Scheldt InformationCenter coordinates (with or without cooperation of other institutes) Scheldt-related projects. In all activities, the different functions of the estuary, safety, policy and management are central issues. By informing everybody about the River Scheldt, the institute hopes to enlarge the involvement and public awareness of this estuary, a river so important for the delta-area in the South-West of The Netherlands as well as for Flanders, Belgium
Gezond zorgvastgoed met Zorgvastgoedmatrix:portfolioanalyse met de BCG-matrix in zorgvastgoed
Onderzoek naar de waterkwaliteit in drie oesterbewaarsystemen te Yerseke gedurende het seizoen 1981 - 1982
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
To assess the therapeutic activity of accelerated cisplatin and high-dose epirubicin with erythropoietin and G-CSF support as induction therapy for patients with stage IIIa-N2 non-small-cell lung cancer (NSCLC). Patients with stage IIIa-N2 NSCLC were enrolled in a phase II trial. They received cisplatin 60 mg m−2 and epirubicin 135 mg m−2 every 2 weeks for three courses combined with erythropoietin and G-CSF. Depending on results of clinical response to induction therapy and restaging, patients were treated with surgery or radiotherapy. In total, 61 patients entered from March 2001 to April 2004. During 169 courses of induction chemotherapy, National Cancer Institute of Canada (NCI-C) grade III/IV leucocytopenia was reported in 35 courses (20.7%), NCI-C grade III/IV thrombocytopenia in 26 courses (15.4%) and NCI-C grade III/IV anaemia in six courses (3.6%). Main cause of cisplatin dose reduction was nephrotoxicity (12 courses). Most patients received three courses. There were no chemotherapy-related deaths. Three patients were not evaluable for clinical response. Twenty-eight patients had a partial response (48.3%, 95% CI: 36–61.1%), 24 stable disease and six progressive disease. After induction therapy, 30 patients underwent surgery; complete resection was achieved in 19 procedures (31.1%). Radical radiotherapy was delivered to 25 patients (41%). Six patients were considered unfit for further treatment. Median survival for all patients was 18 months. Response rate of accelerated cisplatin and high-dose epirubicin as induction chemotherapy for stage IIIa-N2 NSCLC patients is not different from more commonly used cisplatin-based regimen
Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil
Combined Modality Treatment for Locally-Advanced Non-Small-Cell Lung Cancer: The ongoing search for optimal management
Smit, E.F. [Promotor]Senan, S. [Promotor
- …